Stay updated with breaking news from Simon Harnest. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of...
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman...
EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive
Metagenomi's gene-editing toolbox now includes CRISPR associated transposase (CAST) systems and a novel type V CRISPR system.
Metagenomi's gene-editing toolbox now includes CRISPR associated transposase (CAST) systems and a novel type V CRISPR system.